Search Results for: Oral Delivery of Peptides by
Articles
July 17, 2011
7/19/2011 July 17, 2011
Catalent & Sanwa Announce Exclusive License Agreement Catalent Pharma Solutions and Sanwa Kagaku Kenkyusho Co., Ltd. have recently entered into...
July 17, 2011
Zogenix & DURECT Announce Agreement for Antipsychotic Product Candidate July 17, 2011
Zogenix, Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and...
May 19, 2011
5/24/2011 May 19, 2011
Sartorius Stedim Biotech & RAUMEDIC Sign Partnership Agreement Sartorius Stedim Biotech (SSB), an international leading pharma and biotech supplier, and...
May 5, 2011
5/10/2011 May 5, 2011
QRxPharma Completes Patient Enrolment of Phase III Comparative Safety Study QRxPharma Limited recently announced it has completed patient enrolment for...
February 27, 2011
3/1/2011 February 27, 2011
Elan & PPD Announce Global Business Relationship in Drug Development Elan, plc and PPD, Inc. recently announced they have formed...
January 12, 2011
1/18/2011 January 12, 2011
Amgen & Xencor to Co-Develop Novel Antibody; Deal Worth $500 Million Xencor, Inc. and Amgen recently announced they will collaborate to...
August 31, 2022
WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration
Peptide therapeutics are a hot topic in pharmaceutical R&D. While most peptides are administered parenterally, oral delivery of peptide therapeutics...
April 13, 2021
Where Do We Stand on Poorly Soluble Drugs and Peptides in Oral Delivery?
The Rule of 5 suggests that, for oral bioavailability, a better chance for oral absorption is obtained when the molecules are within the parameters of the Rule of 5’. However, the pharmaceutical industry is achieving oral efficacy with drugs that exceed….
August 31, 2023
WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination
This paper covers the benefits of the LBF and capsules combination in dosage form developments, an efficient technology platform to bring efficient and differentiated products to the market.
May 4, 2022
WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges
Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered...
